Table 1.
Clinical features of 144 patients and their associations with regression patterns.
| Factors | Primary cohort |
P value | Validation cohort |
P value | ||
|---|---|---|---|---|---|---|
| Type 1 regression | Type 2 regression | Type 1 regression | Type 2 regression | |||
| Age (years), mean ± SD | 50.24±9.33 | 47.82±8.89 | 0.344 | 48.50±9.32 | 49.25±13.56 | 0.709 |
| Menopausal status | 0.877 | 0.524 | ||||
| Premenopausal | 59 (71.1%) | 13 (76.5%) | 25 (69.4%) | 4 (50.0%) | ||
| Postmenopausal | 24 (28.9%) | 4 (23.5%) | 11 (30.6%) | 4 (50.0%) | ||
| ER status | 0.014 | 0.652 | ||||
| ≤1% | 36 (43.4%) | 2 (11.8%) | 8 (22.2%) | 3 (37.5%) | ||
| >1% | 47 (56.6%) | 15 (88.2%) | 28 (77.8%) | 5 (62.5%) | ||
| PR status | 0.090 | 0.423 | ||||
| ≤1% | 38 (45.8%) | 4 (23.5%) | 10 (27.8%) | 4 (50.0%) | ||
| >1% | 45 (54.2%) | 13 (76.5%) | 26 (72.2%) | 4 (50.0%) | ||
| HER2 status | 0.797 | 0.695 | ||||
| Positive | 37 (44.6%) | 7 (41.2%) | 11 (30.6%) | 3 (37.5%) | ||
| Negative | 46 (55.4%) | 10 (58.8%) | 25 (69.4%) | 5 (62.5%) | ||
| Ki67 status | 0.258 | 1 | ||||
| ≤20% | 16(19.3%) | 6(35.3%) | 12(33.3%) | 3(37.5%) | ||
| >20% | 67(80.7%) | 11(64.7%) | 24(66.7%) | 5(62.5%) | ||
| T stage | 0.390 | 0.080 | ||||
| T2 | 73 (88.0%) | 13 (76.5%) | 35 (97.2%) | 6 (75.0%) | ||
| T3–4 | 10 (12.0%) | 4 (23.5%) | 1 (2.8%) | 2 (25.0%) | ||
| N stage | 0.304 | 0.053 | ||||
| 0 | 49 (59.1%) | 7 (41.2%) | 20 (55.5%) | 1 (12.5%) | ||
| 1 | 29 (34.9%) | 7 (41.2%) | 12 (33.3%) | 4 (50.0%) | ||
| 2 | 4 (4.8%) | 2 (11.7%) | 2 (5.6%) | 3 (37.5%) | ||
| 3 | 1 (1.2%) | 1 (5.9%) | 2 (5.6%) | 0 (0.0%) | ||
| Molecular subtype | 0.050 | 0.464 | ||||
| Luminal | 47 (56.6%) | 15 (88.2%) | 29 (80.6%) | 5 (62.5%) | ||
| HER2 over-expressed | 19 (22.9%) | 1 (5.9%) | 3 (8.3%) | 2 (25.0%) | ||
| TNBC | 17 (20.5%) | 1 (5.9%) | 4 (11.1%) | 1 (12.5%) | ||
| NAC regimen | 1.000 | 0.710 | ||||
| Anthracycline based | 22 (26.5%) | 4 (23.5%) | 15 (41.7%) | 4 (50.0%) | ||
| Non-anthracycline based | 61 (73.5%) | 13 (76.5%) | 21 (58.3%) | 4 (50.0%) | ||
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy.